Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Latisse (Bimatoprost) ( CAS 155206-00-1) Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Medicine Grade
1.3.3 Cosmetic Grade
1.4 Market Segment by Application
1.4.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Medicine
1.4.3 Cosmetic
1.4.4 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue (2015-2026)
2.1.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue (2015-2026)
2.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales (2015-2026)
2.2 Latisse (Bimatoprost) ( CAS 155206-00-1) Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Regions (2015-2020)
2.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Regions (2015-2020)
2.3 Global Top Latisse (Bimatoprost) ( CAS 155206-00-1) Regions (Countries) Ranking by Market Size
2.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Industry Trends
2.4.1 Latisse (Bimatoprost) ( CAS 155206-00-1) Market Top Trends
2.4.2 Market Drivers
2.4.3 Latisse (Bimatoprost) ( CAS 155206-00-1) Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Latisse (Bimatoprost) ( CAS 155206-00-1) Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Latisse (Bimatoprost) ( CAS 155206-00-1) Manufacturers by Sales (2015-2020)
3.1.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Manufacturers (2015-2020)
3.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Latisse (Bimatoprost) ( CAS 155206-00-1) Sales in 2019
3.2 Global Top Manufacturers Latisse (Bimatoprost) ( CAS 155206-00-1) by Revenue
3.2.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Manufacturers (2015-2020)
3.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Latisse (Bimatoprost) ( CAS 155206-00-1) as of 2019)
3.4 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Latisse (Bimatoprost) ( CAS 155206-00-1) Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Latisse (Bimatoprost) ( CAS 155206-00-1) Market
3.7 Key Manufacturers Latisse (Bimatoprost) ( CAS 155206-00-1) Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Historic Market Review by Type (2015-2020)
4.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Market Share by Type (2015-2020)
4.1.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Market Share by Type (2015-2020)
4.1.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price by Type (2015-2020)
4.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast by Type (2021-2026)
4.2.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast by Type (2021-2026)
4.2.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price Forecast by Type (2021-2026)
5 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Size by Application
5.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Historic Market Review by Application (2015-2020)
5.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Market Share by Application (2015-2020)
5.1.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Market Share by Application (2015-2020)
5.1.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price by Application (2015-2020)
5.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast by Application (2021-2026)
5.2.3 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast by Application (2021-2026)
5.2.4 Latisse (Bimatoprost) ( CAS 155206-00-1) Price Forecast by Application (2021-2026)
6 North America
6.1 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
6.2 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
6.3 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
6.4 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
6.4.1 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
6.4.2 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
7.2 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
7.3 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
7.4 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
7.4.1 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
7.4.2 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
8.2 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
8.3 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
8.4 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Regions
8.4.1 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Regions
8.4.2 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Company
9.2 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
9.3 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
9.4 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
9.4.1 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
9.4.2 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Type
10.2 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Application
10.3 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Breakdown Data by Countries
10.3.1 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Sales by Countries
10.3.2 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Allergan plc (AbbVie Inc.)
11.1.1 Allergan plc (AbbVie Inc.) Corporation Information
11.1.2 Allergan plc (AbbVie Inc.) Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Allergan plc (AbbVie Inc.) Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Allergan plc (AbbVie Inc.) Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.1.5 Allergan plc (AbbVie Inc.) SWOT Analysis
11.1.6 Allergan plc (AbbVie Inc.) Recent Developments
11.2 Sandoz(Novartis)
11.2.1 Sandoz(Novartis) Corporation Information
11.2.2 Sandoz(Novartis) Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Sandoz(Novartis) Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Sandoz(Novartis) Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.2.5 Sandoz(Novartis) SWOT Analysis
11.2.6 Sandoz(Novartis) Recent Developments
11.3 Hi-Tech Pharmacal
11.3.1 Hi-Tech Pharmacal Corporation Information
11.3.2 Hi-Tech Pharmacal Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Hi-Tech Pharmacal Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Hi-Tech Pharmacal Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.3.5 Hi-Tech Pharmacal SWOT Analysis
11.3.6 Hi-Tech Pharmacal Recent Developments
11.4 Apotex Inc.
11.4.1 Apotex Inc. Corporation Information
11.4.2 Apotex Inc. Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Apotex Inc. Latisse (Bimatoprost) ( CAS 155206-00-1) Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Apotex Inc. Latisse (Bimatoprost) ( CAS 155206-00-1) Products and Services
11.4.5 Apotex Inc. SWOT Analysis
11.4.6 Apotex Inc. Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Channels
12.2.2 Latisse (Bimatoprost) ( CAS 155206-00-1) Distributors
12.3 Latisse (Bimatoprost) ( CAS 155206-00-1) Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.1.1 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast by Regions (2021-2026)
13.1.2 Global Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.2.2 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.2.3 North America Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.3.2 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.3.3 Europe Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.4.2 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.5.2 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.5.3 Latin America Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Latisse (Bimatoprost) ( CAS 155206-00-1) Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Allergan plc (AbbVie Inc.)、Sandoz(Novartis)、Hi-Tech Pharmacal、Apotex Inc.
【免責事項】
https://www.globalresearch.jp/disclaimer